Latest Public Health News

Island Pharmaceuticals has secured membership in the Medical Countermeasures Coalition, positioning its antiviral Galidesivir for critical US government stockpiling and regulatory milestones.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

Bio-Gene Technology’s natural insecticide Qcide® has earned organic listing status from the US Organic Materials Review Institute, marking a pivotal step for its entry into the organic pest control market.

Island Pharmaceuticals will host a webinar to discuss the FDA's feedback on the clinical development and regulatory approval of its antiviral drug Galidesivir, including key considerations under the FDA's Animal Rule and Priority Review Voucher eligibility.

Unith Ltd has secured new contracts and expanded its strategic partnerships while advancing its ISO 27001 certification, signaling strong momentum in its AI digital human technology business.

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.

Bio-Gene Technology Limited reports significant progress in Q1 FY26, unveiling new product opportunities and positive efficacy data, alongside securing US Department of Defense grants.

Cobalt Blue Holdings advances its Kwinana Cobalt Refinery with a critical Works Approval and secures letters of intent covering 70% of initial production, while its Broken Hill Cobalt Project gains a three-year Major Project Status extension.

Unith Ltd reports a 32% rise in Q1 FY26 cash receipts and unveils its breakthrough Streaming Avatars technology, alongside a successful $1.85 million capital raise.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Cochlear Limited reports steady FY25 financials alongside the launch of its innovative Nucleus Nexa cochlear implant system, setting the stage for projected double-digit profit growth in FY26.